Back to Search Start Over

273P Talazoparib (TALA) for patients with germline BRCA1/2 mutated (gBRCA1/2mut) advanced breast cancer (ABC): Characteristics of patients who experienced hematologic toxicity in the phase III EMBRACA trial.

Authors :
Hurvitz, S.A.
Rugo, H.S.
Ettl, J.
Martin, M.
Roche, H.
Lee, K-H.
Goodwin, A.
Usari, T.
Lanzalone, S.
Guenzel, C.A.
Blum, J.
Litton, J.K.
Source :
Annals of Oncology. 2021 Supplement 5, Vol. 32, pS482-S482. 1p.
Publication Year :
2021

Subjects

Subjects :
*BREAST cancer
*GERM cells

Details

Language :
English
ISSN :
09237534
Volume :
32
Database :
Academic Search Index
Journal :
Annals of Oncology
Publication Type :
Academic Journal
Accession number :
152688904
Full Text :
https://doi.org/10.1016/j.annonc.2021.08.556